News
Taffix® blocks the Delta Variant of SARS-CoV-2 in addition to the Alpha (UK) and Beta (South African) Variant
August 2, 2021
Nasus Pharma announces data demonstrating in vitro efficacy of Taffix intranasal antiviralspray against the new highly infectious Delta variant of SARS-CoV-2 TEL AVIV, Israel, July
Nasus Pharma Announces Positive Results from a Pilot Clinical Study of FMXIN002 Intranasal Powder Epinephrine Spray in
June 23, 2021
Results demonstrate rapid epinephrine absorption- for potentially quicker rescue ofpatients in anaphylactic shock Tel Aviv Israel June 23 2021– Nasus Pharma Ltd a clinical-stage biopharmaceuticalcompany
Nasus Pharma announces positive Results in Naloxone Pivotal Trial.
April 13, 2021
Nasus Pharma Announces Positive Results in Pivotal Trial of FMXIN001 Naloxone Powder-Based Nasal Spray for the Treatment of opioid overdose • Significantly higher rapid absorption
More News
A new product – TaffiX ™
August 1, 2020
TaffiX ™ Nasal Powder Spray Device against Viruses, i24
August 1, 2020
